A QSTR-Based Expert System to Predict Sweetness of Molecules.

Front Chem

Milano Chemometrics and QSAR Research Group, Department of Earth and Environmental Sciences, University of Milano-BicoccaMilan, Italy.

Published: July 2017

This work describes a novel approach based on advanced molecular similarity to predict the sweetness of chemicals. The proposed Quantitative Structure-Taste Relationship (QSTR) model is an expert system developed keeping in mind the five principles defined by the Organization for Economic Co-operation and Development (OECD) for the validation of (Q)SARs. The 649 sweet and non-sweet molecules were described by both conformation-independent extended-connectivity fingerprints (ECFPs) and molecular descriptors. In particular, the molecular similarity in the ECFPs space showed a clear association with molecular taste and it was exploited for model development. Molecules laying in the subspaces where the taste assignation was more difficult were modeled trough a consensus between linear and local approaches (Partial Least Squares-Discriminant Analysis and -nearest-neighbor classifier). The expert system, which was thoroughly validated through a Monte Carlo procedure and an external set, gave satisfactory results in comparison with the state-of-the-art models. Moreover, the QSTR model can be leveraged into a greater understanding of the relationship between molecular structure and sweetness, and into the design of novel sweeteners.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524730PMC
http://dx.doi.org/10.3389/fchem.2017.00053DOI Listing

Publication Analysis

Top Keywords

expert system
12
predict sweetness
8
molecular similarity
8
qstr model
8
molecular
5
qstr-based expert
4
system predict
4
sweetness molecules
4
molecules work
4
work describes
4

Similar Publications

Purpose: We hypothesised that applying radiomics to [F]PSMA-1007 PET/CT images could help distinguish Unspecific Bone Uptakes (UBUs) from bone metastases in prostate cancer (PCa) patients. We compared the performance of radiomic features to human visual interpretation.

Materials And Methods: We retrospectively analysed 102 hormone-sensitive PCa patients who underwent [F]PSMA-1007 PET/CT and exhibited at least one focal bone uptake with known clinical follow-up (reference standard).

View Article and Find Full Text PDF

Introduction: The synergistic combination of histone deacetylase inhibitors and platinum-based medicines represents a promising therapeutic strategy to efficacy and overcome drug resistance in cancer therapy, necessitating a comprehensive on their molecular interactions and clinical potential.

Areas Covered: The objective of presented review is to investigate the molecular pathways of platinum medicines and HDAC inhibitors. A comprehensive literature review from 2011 to 2024 was conducted across multiples databases like MEDLINE, PubMed, Google Scholar, Science Direct, Scopus and official websites of ClinicalTrial.

View Article and Find Full Text PDF

Background: Brivaracetam (BRV) is a novel drug for the treatment of epilepsy. This study aimed to detect and characterize adverse events (AEs) associated with BRV from the first quarter of 2016 to the second quarter of 2024 using the U.S.

View Article and Find Full Text PDF

Objective: The fabrication of furosemide (FSM) with enhanced oral bioavailability and encapsulation was achieved using a nanostructured lipid carriers (NLCs) drug delivery system.: The uniform drug distribution is a barrier due to its low dose. The lipid-based delivery system was selected based on its poor solubility and permeability, limiting its poor partitioning and solubility in water-based polymeric delivery systems.

View Article and Find Full Text PDF

Background: Glucagon-like peptide-1 (GLP-1) agonists are commonly prescribed for type 2 diabetes mellitus (T2DM). Concerns have emerged regarding their potential link to diabetic retinopathy (DR).

Methods: To evaluate the association between GLP-1 agonists and DR, a disproportionality analysis was conducted using FDA Adverse Event Reporting System (FAERS) data from Q4/2003 to Q2/2024 via OpenVigil 2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!